ICPT—Lots of discussion on Twitter about NASH phase-3 design. I think REGENERATE will be a tough trial to bring home—even FLINT-like results might not be good enough.
(ICPT refused to disclose the statistical power on today's CC.)
All told, ICPT's valuation does not properly discount the risk of phase-3 failure in NASH, IMO.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.